Dominion Biotech provides a platform of patient‑derived cell (PDC) models that are fully genetically characterized and available for high‑throughput drug screening across diverse cancer types and clinically relevant mutations. Their service also includes immunotherapy testing using autologous peripheral blood mononuclear cells paired with the same tumor cells, with AI‑driven analytics delivering integrated, actionable reports for pharmaceutical and biotech research teams.
Funding
Funding not disclosed
Founders
Product
Problem
Pharmaceutical and biotech researchers often rely on limited cell line models that do not capture the genetic diversity and tumor microenvironment of patient cancers, leading to poor translation of preclinical findings into clinical success. Additionally, evaluating immunotherapy responses is hampered by the lack of matched patient immune cells in standard assays.
Solution
Dominion Biotech offers a platform built around patient-derived cell (PDC) models that are genetically characterized through next‑generation sequencing and comprehensive RNA profiling. Their high‑throughput drug screening service tests compounds across a biobank covering multiple cancer types and clinically relevant mutations, enabling early go/no‑go decisions and identification of responder subpopulations. For immuno‑oncology, Dominion pairs autologous peripheral blood mononuclear cells with the corresponding tumor cells to assess efficacy and resistance mechanisms. Results are integrated with AI‑driven analytics that combine genomic, phenotypic, and clinical data to produce actionable reports for drug development teams.
Target Audience
Primary customers are pharmaceutical and biotechnology companies, as well as academic and contract research organizations, that require predictive preclinical models for drug discovery, lead optimization, and immunotherapy development.
Features
- Extensive PDC biobank representing diverse tissue types and key mutations (e.g., EGFR, KRAS, BRAF, PIK3CA, BRCA1/2) across breast, lung, melanoma, colorectal, pancreatic, and ovarian cancers
- High‑throughput screening capability for single agents and combination therapies with flexible assay formats
- Immunotherapy testing using patient‑matched autologous PBMCs to evaluate immune response and combination strategies
- Full genetic characterization of each sample via NGS, RNA‑seq (including PD‑L1 and checkpoint markers), and a bioinformatics pipeline
- Over 100 high‑content screening (HCS) assays available, with custom assay design and rigorous validation using reference compounds
- Integrated data analysis platform employing advanced statistics, AI models, and self‑learning algorithms to enhance predictive power
- Detailed, actionable reporting that combines molecular profiling, assay results, and clinical context for decision‑making